First milestone payment for ADC-1013
Alligator Bioscience receives milestone payment from the CD40 Agonistic Immuno-Oncology Antibody ADC-1013 project with Johnson & Johnson Innovation Alligator Bioscience AB is a privately held Swedish biotech company developing immuno-oncology antibodies for directed immunotherapy of cancer. Alligator granted Johnson & Johnson an exclusive, worldwide license to Alligator’s clinical candidate ADC-1013 in an agreement entered in August 2015. According to this agreement, Janssen will be responsible for developing ADC-1013 and will assume responsibility for the clinical studies once the